Mirae Asset Capital, a diversified asset manager providing innovative solutions worldwide, led a $75m Series C funding round in Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, with participation from Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squib, Johnson & Johnson Innovation, The Column Group, Atlas Venture, Droia Ventures, GV, EcoR1 Capital, AbbVie Ventures, The Mark Foundation for Cancer Research and Timefolio Capital. "Accent’s focus on targeting cancer cell vulnerabilities in a specific and robust way really stood out as we were evaluating companies for our first investment. They have assembled an incredible team with a successful track record of drug development, and we are excited to partner with the other seasoned investors to support Accent at this pivotal time," Naveen Krishnan, Mirae Asset Capital Managing Director.